1.?Jing Pan, Shiyu Zuo, Biping Deng, Xiuwen Xu, Chuo Li, Qinlong Zheng, Zhuojun Lin, Weiliang Song, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Alex H. Chang, Xiaoming Feng, Chunrong Tong; Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL.?Blood?blood.2019003293.（*Co-corresponding author. IF：16.562）?
2.Jing Pan, Qing Niu, Biping Deng, Shuangyou Liu, Tong Wu, Zhiyong Gao, Zhaoli Liu, Yue Zhang, Xiaomin Qu, Yanlei Zhang, Shaohui Liu, Zhuojun Ling, Yuehui Lin, Yongqiang Zhao, Yanzhi Song, Xiyou Tan, Yan Zhang, Zhihui Li, Zhichao Yin, Bingzhen Chen, Xinjian Yu, Ju Yan, Qinlong Zheng, Xuan Zhou, Jin Gao, Alex H. Chang*, Xiaoming Feng*, Chunrong Tong*. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia. 2019. Accepted.（*Co-corresponding author. IF：12.10）
3.Ning Li, Shaohui Liu, Mingjiao Sun, Wei Chen, Xiaogang Xu, Zhu Zeng, YeminTang，Yongquan Dong, Alex H. Chang*, Qiong Zhao*. Chimeric antigen receptor-modified T cells redirected to EphA2 for the immunotherapy of non-small cell lung cancer. Transl Oncol. 2018 Feb;11(1):11-17 （*Co-corresponding author. IF：2.93）
4. Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, Wu YN, Deng ZL, Zhang YL,Liu SH, Wu T, Lu PH, Lu DP, Chang AH（張鴻聲）*, Tong CR*. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute?lymphoblastic leukemia patients. Leukemia. 2017 Dec;31(12):2587-2593. （*共同通訊作者， 影響因子：12.10）
5. B. Deng, A. H. Chang , J. Yang, J. Pan, X. Zhang, Y. Lin, Y. Wu, Z. Deng, P. Lu, T. Wu, Z. Liu , Y. Zhang and C. Tong, MD . Safety and Efficacy of Low Dose CD19 Targeted Chimeric Antigen Receptor T (CAR-T) Cell Immunotherapy in 47 Cases with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL). Oral presentation# 649. ASH 58th Annual Meeting & Exposition, 2016 Dec.
6. Sadelain M, Chang A（張鴻聲）, Lisowski L. Supplying Clotting Factors From Hematopoietic Stem Cell-derived Erythroid and Megakaryocytic Lineage Cells. Molecular Therapy. 2009 Dec;17(12):1994-9.（影響因子：6.83）
7. Chang A.H. （張鴻聲）*, Stephan M.T., Lisowski L., Sadelain M. Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice. Molecular Therapy. 2008 Oct;16(10):1745-52. （*通訊作者， 影響因子：6.83）
8. Stephan M.T., Ponomarev, V., Brentjens, R.J., Chang A.H. （張鴻聲）, Dobrenkov, KV, Heller, G. & Sadelain M. T cell-encoded CD28 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nature Medicine. 2007 Dec;13(12):1440-9. （影響因子：24.30）
9. Chang A.H. （張鴻聲）, Sadelain M. Review: Genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the LTR, and the promise of lineage-restricted vectors. Molecular Therapy. 2007 15(3): 445-456. （影響因子：6.83）
10. Chang A.H. （張鴻聲）, Stephan M.T., Sadelain M. Stem cell-derived erythroid cells mediate long-term systemic protein delivery. Nature Biotechnology. 2006 24(8): 1017-1021. （影響因子：32.44）
滬公網(wǎng)安備31011002002771號